Detailed Information on Publication Record
2021
Thermostable FGF2 Polypeptide, Use Thereof
DVOŘÁK, Petr, Pavel KREJČÍ, Lukáš BÁLEK, Lívia EISELLEOVÁ, Žaneta KONEČNÁ et. al.Basic information
Original name
Thermostable FGF2 Polypeptide, Use Thereof
Authors
DVOŘÁK, Petr (203 Czech Republic, guarantor, belonging to the institution), Pavel KREJČÍ (203 Czech Republic, belonging to the institution), Lukáš BÁLEK (203 Czech Republic, belonging to the institution), Lívia EISELLEOVÁ (703 Slovakia, belonging to the institution), Žaneta KONEČNÁ (203 Czech Republic, belonging to the institution), Pavel DVOŘÁK (203 Czech Republic, belonging to the institution), David BEDNÁŘ (203 Czech Republic, belonging to the institution), Jan BREZOVSKÝ (203 Czech Republic, belonging to the institution), Eva ŠEBESTOVÁ (203 Czech Republic, belonging to the institution), Radka CHALOUPKOVÁ (203 Czech Republic, belonging to the institution), Veronika ŠTĚPÁNKOVÁ, Pavel VAŇÁČEK, Zbyněk PROKOP, Jiří DAMBORSKÝ (203 Czech Republic, belonging to the institution) and Michaela BOSÁKOVÁ (203 Czech Republic, belonging to the institution)
Edition
Number: SG11201804402W, Publisher: Intellectual Property Office of Singapore (IPOS), Place of publication: Singapur, Owner's name: Masarykova univerzita; Enantis s.r.o. 2021
Other information
Language
English
Type of outcome
Patent
Country of publisher
Singapore
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
RIV identification code
RIV/00216224:14310/21:00121632
Organization
Přírodovědecká fakulta – Repository – Repository
Keywords in English
Fibroblast Growth Factor 2; FGF2
Links
LO1214, research and development project.
Změněno: 1/6/2022 02:28, RNDr. Daniel Jakubík
Abstract
V originále
The invention provides an isolated thermostable polypeptide possessing FGF2 activity and having at least 85% sequence identity to SEQ ID NO: 2 (FGF2 wt) or a functional fragment thereof, and comprising at least one amino acid substitution R31L and the use thereof in the cell biology research, regenerative medicine and related medical applications or cosmetics. Further it discloses a culture medium comprising subjected FGF2 suitable for culturing a human pluripotent stem cells involving both human embryonic stem cells and induced pluripotent stem cells.